Zhitong Finance App News, Eling Pharmaceutical (002603.SZ) issued an announcement. Beijing Eling Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Acceptance” approved and issued by the State Drug Administration on October 21, 2026, and the clinical trial application for a new bone and joint granule drug was accepted. The intended functions of bone and joint health granules are: supplement kidney and bone health, activate blood circulation, and relieve muscle pain.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.